Resveratrol Studies Suggest Broad Implications for SIRT1 Activation in Neurodegenerative Diseases of Aging Such as Alzheimer's D
26 June 2007 - 10:00PM
Business Wire
Sirtris Pharmaceuticals, Inc. (NASDAQ: SIRT), a biopharmaceutical
company focused on discovering and developing small molecule drugs
to treat diseases of aging, announced today that activation of
SIRT1, a member of the sirtuin family of enzymes, was shown to
protect against neurodegenerative diseases such as Alzheimer�s
Disease and Amyotrophic Lateral Sclerosis in animal models. These
findings appear in an article published in Volume 26, Number 13 of
The European Molecular Biology Organization Journal (EMBO), Kim et
al., 2007 entitled �SIRT1 deacetylase protects against
neurodegeneration in models for Alzheimer's disease and amyotrophic
lateral sclerosis� which is also available now in the advance
online publication. It is well established that a progressive loss
of neurons with age underlies a variety of debilitating
neurological disorders including Alzheimer�s Disease and
Amyotrophic Lateral Sclerosis (ALS), neurodegenerative diseases
which have been associated with reduced mitochondrial function.
Sirtuins are a recently discovered class of enzymes that appear to
affect the aging process in mammals and increase the number and
function of mitochondria. According to the findings in this paper,
resveratrol, a SIRT1 activator, reduced the loss of neuronal
function in the brain (hippocampus) and prevented learning
impairment in a well established animal model of Alzheimer�s
Disease. This response was associated with SIRT1 dependent
deacetylation of PGC1a. Resveratrol also promoted neuronal survival
in cell based models of Alzheimer�s Disease and ALS. The three
senior authors of the EMBO article include Sirtris co-founder and
co-chair of the Scientific Advisory Board (SAB), David A. Sinclair,
Ph.D., Department of Pathology and Paul F. Glenn Laboratories for
the Biological Mechanisms of Aging, Harvard Medical School, and
Sirtris SAB members Li-Huei Tsai, Ph.D. Howard Hughes Medical
Institute, Picower Institute for Learning and Memory, Massachusetts
Institute of Technology and Pere Puigserver, Ph.D., Dana Farber
Cancer Institute and Department of Cell Biology, Harvard Medical
School. �This work is significant because it shows that a SIRT1
activator can protect against neurodegeneration, highlighting the
therapeutic potential of SIRT1 activators,� said David Sinclair.
Christoph Westphal, M.D., Ph.D., Chief Executive Officer of Sirtris
Pharmaceuticals added �These new data support our belief in SIRT1
as a therapeutic target for neurodegenerative disease, which
expands the potential of our pipeline of SIRT1 modulators designed
to treat a number of diseases of aging such as metabolic and
mitochondrial disorders, and now neurological disorders.� Online
copies of the article can be obtained at:
http://www.nature.com/emboj About Sirtris Pharmaceuticals Sirtris
Pharmaceuticals is a biopharmaceutical company focused on
discovering and developing proprietary, orally available, small
molecule drugs with the potential to treat diseases associated with
aging, including metabolic diseases such as Type 2 Diabetes. Our
drug candidates are designed to mimic certain beneficial health
effects of calorie restriction, without requiring a change in
eating habits, by activation of sirtuins, a recently discovered
class of enzymes that control the aging process. The company's
headquarters are in Cambridge, Massachusetts. This press release
contains forward-looking statements within the meaning of the
Private Securities Litigation Reform Act of 1995 concerning Sirtris
Pharmaceuticals, its product candidates, and those candidates'
clinical potential. These forward-looking statements about future
expectations, plans and prospects of Sirtris Pharmaceuticals
involve significant risks, uncertainties and assumptions, including
risks related to the lack of results that would provide a basis for
predicting whether any of the Company�s product candidates will be
safe or effective, or receive regulatory approval, the Company's
potential inability to initiate and complete preclinical studies
and clinical trials for its product candidates, the fact that none
of the Company's product candidates has received regulatory
approvals, the potential inability of the�Company to gain market
acceptance of the Company's product candidates, and those other
risks factors�that can be found in the�Company's filings with the
Securities and Exchange Commission. Actual results may differ
materially from those Sirtris Pharmaceuticals contemplated by these
forward-looking statements. Sirtris Pharmaceuticals does not
undertake to update any of these forward-looking statements to
reflect a change in its views or events or circumstances that occur
after the date of this release.
Sierra Natl BK Tehachapi Calif (MM) (NASDAQ:SIRT)
Historical Stock Chart
From Jun 2024 to Jul 2024
Sierra Natl BK Tehachapi Calif (MM) (NASDAQ:SIRT)
Historical Stock Chart
From Jul 2023 to Jul 2024
Real-Time news about Sierra Natl BK Tehachapi Calif (MM) (NASDAQ): 0 recent articles
More Sirtris Pharmaceuticals, Inc. News Articles